Natera, Inc. (NTRA) · Nov 5, 2026 · Earnings

Natera earnings beat as oncology volumes surge and guidance jumps

Beat — Revenue $794M vs ~$708M consensus; FY26 midpoint $3.02B vs $2.88B

Natera’s Q3 earnings show accelerating Signatera volumes, a large revenue beat and higher 2026 guidance, though spending remains elevated.

Natera is scaling from a broad genetic-testing company into an oncology-led precision-medicine platform, with Signatera’s minimal residual disease testing driving the fastest growth while the company invests heavily in clinical trials, early cancer detection and international expansion. Its prior quarter had already shown record oncology volume and a $100 million midpoint guidance increase, so the direction was known; this filing shows the acceleration is continuing.

The core business materially outperformed the published bar. Revenue reached $794.0 million, well above the roughly $708 million Q3 consensus, while clinical MRD volume rose to about 316,000 tests from 202,000 a year earlier. The filing also says this was the second consecutive quarter with more than 30,000 sequential MRD-unit growth, supporting the view that Signatera adoption—not just accounting noise—is carrying the business. The consensus comparison is external; the company’s own filing states, “Revenue of $794M in Q3 2026 vs $592M in Q3 2025; year-over-year growth of ~34%.”

Q3 2026Q3 2025Consensus / prior guide
Total revenue (Financial Review)$794.0M (+34.1%)$592.2M~$707.5M
Clinical MRD tests (Financial Highlights)~316K (+56%)~202K
Gross margin (Financial Review)64.7%64.9%
Net loss per diluted share (Financial Review)$(0.42)$(0.64)~$(0.28)
FY26 revenue guide midpoint (Guidance)$3.020B$2.880B prior midpoint

Guidance moved from strong execution to a higher operating base. Natera raised its 2026 revenue range to $3.005 billion–$3.035 billion from $2.850 billion–$2.910 billion, a $140 million midpoint increase, while maintaining its positive cash-flow outlook. The filing explicitly attributes the increase to continued volume growth, conservative average selling prices and strong oncology contribution, and says, “Raising 2026 annual revenue guidance by $140million.”

The main offset is that the company is spending aggressively to convert growth into a larger platform. R&D and SG&A are both rising, with heavier spending on the FIND colorectal-screening study, Signatera trials, early cancer detection and marketing. The quarter’s reported GAAP loss of $0.42 per diluted share was worse than the roughly $0.28 consensus loss, although the filing does not identify whether that external estimate uses the same GAAP definition. Gross margin was essentially flat year over year at 64.7%, despite better underlying performance excluding revenue true-ups.

The longer-term oncology story gained more support, but the biggest new opportunities remain execution-dependent. The filing points to 316,000 quarterly MRD tests, seven new pharma partnerships since May, Japan approvals for colorectal and bladder-cancer uses, and a 30,000-patient colorectal screening cohort now fully enrolled. Those developments broaden Signatera’s commercial and clinical reach, but Japan still awaits reimbursement and pricing, while early cancer detection remains on the path toward FDA-enabling data rather than a commercial launch.

Bottom line: This was a meaningful execution beat: Signatera volumes are accelerating, revenue expectations moved higher, and the 2026 growth base is stronger than before. The caveat is not demand but conversion—Natera is still accepting heavy investment and a sizable loss to build the next phase of the platform.

What to watch next

Japan Signatera launch after year-end reimbursement and pricing

Original filing on SEC EDGAR

More Natera, Inc. news

Natera earnings beat as oncology volumes surge and guidance jumps | NTRA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.